NO20042167L - Montelukast granulformulering - Google Patents

Montelukast granulformulering

Info

Publication number
NO20042167L
NO20042167L NO20042167A NO20042167A NO20042167L NO 20042167 L NO20042167 L NO 20042167L NO 20042167 A NO20042167 A NO 20042167A NO 20042167 A NO20042167 A NO 20042167A NO 20042167 L NO20042167 L NO 20042167L
Authority
NO
Norway
Prior art keywords
granule formulation
montelukast
montelukast granule
formulation
relates
Prior art date
Application number
NO20042167A
Other languages
English (en)
Norwegian (no)
Inventor
Brian Down
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042167(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO20042167L publication Critical patent/NO20042167L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20042167A 2001-10-26 2004-05-25 Montelukast granulformulering NO20042167L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33954901P 2001-10-26 2001-10-26
PCT/CA2002/001604 WO2003035036A1 (en) 2001-10-26 2002-10-22 Montelukast granule formulation

Publications (1)

Publication Number Publication Date
NO20042167L true NO20042167L (no) 2004-05-25

Family

ID=23329547

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042167A NO20042167L (no) 2001-10-26 2004-05-25 Montelukast granulformulering

Country Status (26)

Country Link
US (2) US20030096840A1 (xx)
EP (1) EP1441701B1 (xx)
JP (1) JP4420671B2 (xx)
KR (1) KR101094084B1 (xx)
CN (1) CN100591329C (xx)
AT (1) ATE385781T1 (xx)
AU (1) AU2002333134B2 (xx)
BR (1) BR0213477A (xx)
CA (1) CA2463947C (xx)
CY (1) CY1107400T1 (xx)
DE (1) DE60225040T2 (xx)
DK (1) DK1441701T3 (xx)
EC (1) ECSP045082A (xx)
EG (1) EG24380A (xx)
ES (1) ES2298431T3 (xx)
HR (1) HRP20040367B1 (xx)
HU (1) HUP0401670A3 (xx)
IL (1) IL161299A0 (xx)
MX (1) MXPA04003856A (xx)
MY (1) MY148466A (xx)
NO (1) NO20042167L (xx)
PE (1) PE20030638A1 (xx)
PT (1) PT1441701E (xx)
SI (1) SI1441701T1 (xx)
WO (1) WO2003035036A1 (xx)
ZA (1) ZA200402584B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EA021960B1 (ru) 2005-12-30 2015-10-30 Крка, Товарна Здравил, Д.Д., Ново Место Таблетка, содержащая фармацевтически приемлемую соль монтелукаста в аморфной форме, и способ ее получения
PT1818057E (pt) * 2006-02-09 2010-06-18 Teva Pharma Formulações farmacêuticas estáveis de montelucaste de sódio
US8106040B2 (en) 2006-09-26 2012-01-31 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
CN102046202A (zh) * 2008-03-26 2011-05-04 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PT3085381T (pt) 2008-05-21 2018-05-18 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado pela noctúria
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
JP5650532B2 (ja) * 2008-08-18 2015-01-07 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
AU2011234637B2 (en) 2010-03-29 2013-08-29 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 孟鲁司特钠脂质体固体制剂
KR20140108627A (ko) 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
CA2848785A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
AU2013289403B2 (en) 2012-07-12 2017-05-11 Ferring B.V. Diclofenac formulations
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) * 2012-09-12 2014-03-13 Glenmark Generics Ltd. Stable pharmaceutical composition of saxagliptin
CN103520129B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 一种孟鲁斯特钠脉冲释放制剂
CN103520130B (zh) * 2013-10-15 2020-08-04 天垚医药科技发展（上海）有限公司 孟鲁斯特钠择时控释片及其制备方法
CN103520136B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 孟鲁斯特钠脉冲胶囊及其制备方法
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN103720672B (zh) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) * 2015-04-20 2019-03-27 高田製薬株式会社 モンテルカストナトリウム顆粒製剤
CN107595783A (zh) * 2017-06-01 2018-01-19 合肥远志医药科技开发有限公司 一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) * 2017-11-29 2019-06-04 扬子江药业集团有限公司 一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 一种孟鲁司特钠药物组合物
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
CN111110679A (zh) * 2018-10-31 2020-05-08 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) * 2020-01-19 2020-06-09 安徽省先锋制药有限公司 一种孟鲁司特钠颗粒制剂方法
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114224847B (zh) * 2021-12-07 2023-09-15 哈尔滨珍宝制药有限公司 一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) * 2022-02-24 2022-05-03 佑华医药科技有限公司 一种孟鲁司特钠颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
NZ230763A (en) 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
DE68916497T2 (de) 1988-09-30 1994-11-17 Rhone Poulenc Rorer Ltd Pharmazeutisches Granulat.
DK0390435T3 (da) * 1989-03-29 1994-03-21 Takeda Chemical Industries Ltd Blanding indeholdende en forbindelse fra vitamin B gruppen, og fremstilling deraf
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH0967247A (ja) 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd 均一な微粒子製剤の製造方法
CA2236175A1 (en) * 1995-11-02 1997-05-09 Merck Frosst Canada Incorporated New technology for wet granulation
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
DK1041990T3 (da) 1997-12-23 2006-10-02 Schering Corp Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
US6221880B1 (en) * 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20030031720A1 (en) 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
ECSP045082A (es) 2004-06-28
HRP20040367A2 (xx) 2005-06-30
AU2002333134B2 (en) 2007-08-02
CA2463947C (en) 2009-05-19
MXPA04003856A (es) 2004-07-08
US20030096840A1 (en) 2003-05-22
DK1441701T3 (da) 2008-05-26
ZA200402584B (en) 2005-06-29
HUP0401670A3 (en) 2008-08-28
EP1441701A1 (en) 2004-08-04
EP1441701B1 (en) 2008-02-13
EG24380A (en) 2009-04-05
ATE385781T1 (de) 2008-03-15
DE60225040D1 (de) 2008-03-27
MY148466A (en) 2013-04-30
US20080131516A1 (en) 2008-06-05
KR101094084B1 (ko) 2011-12-15
PT1441701E (pt) 2008-04-07
HRP20040367B1 (en) 2012-07-31
SI1441701T1 (sl) 2008-08-31
JP2005510497A (ja) 2005-04-21
CA2463947A1 (en) 2003-05-01
KR20040047961A (ko) 2004-06-05
HUP0401670A2 (hu) 2008-05-28
PE20030638A1 (es) 2003-07-21
JP4420671B2 (ja) 2010-02-24
BR0213477A (pt) 2004-11-03
CN1575163A (zh) 2005-02-02
DE60225040T2 (de) 2009-02-26
ES2298431T3 (es) 2008-05-16
CY1107400T1 (el) 2012-12-19
CN100591329C (zh) 2010-02-24
IL161299A0 (en) 2004-09-27
US8007830B2 (en) 2011-08-30
WO2003035036A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
DK1441701T3 (da) Montelukast-granuleformulering
ATE296619T1 (de) Feste orale dosierungsform von simethicon
SE0203713D0 (sv) Novel compounds
EA199900373A2 (ru) Фармацевтические композиции
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NO20035087D0 (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
CO5590918A2 (es) Formulaciones
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
NO20044916L (no) Preparater av sulfinylacetamid
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
SE9901077D0 (sv) Novel use
SE9801494D0 (sv) Novel use
ATE365455T1 (de) Aminoacetonitril-verbindungen zur bekämpfung von endoparasiten
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
SE0200657D0 (sv) Novel Formulation
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
ATE301933T1 (de) Akarizidpulver

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application